Halozyme Therapeutics hit $1.4B in 2025 revenue, driven by soaring royalties from key drugs, with strong growth expected in 2026.

Japan's panel backs first iPS cell therapies for Parkinson’s and heart disease, pending minister approval.

Boehringer Ingelheim India and NIPER Raebareli signed an MoU on Feb. 19, 2026, to advance pharmaceutical research and education in India.

Fractal AI's Vaidya 2.0, a healthcare AI model, scored 50.1 on a key benchmark, becoming the first to exceed 50, and integrates with India’s digital health systems for real-world medical use.

FDA accepted Roche’s drug combo for ESR1-mutated advanced breast cancer, with review due by Dec. 18, 2026.

Novo Nordisk stock dropped 1.6% on Feb. 19, 2026, despite strong earnings and a new oral diabetes drug, due to weak guidance and competition.

India launched LuSI, a 2.5 kg AI robot simulating newborn breathing, to improve neonatal care training and reduce infant deaths.

India's Health Minister urges AIIMS reforms: patient care, AI integration, and faster hiring.

TREMFYA maintained remission in most ulcerative colitis patients over 3 years with no new safety issues.

Aging men losing Y chromosomes face higher risks of heart disease, cancer, and shorter lives, new study finds.